Biochemical Assessment of Treatment Response in Metastatic Breast Cancer
Author Information
Author(s): M.R. Williams, A. Turkes, D. Pearson, K. Griffiths, R.W. Blamey
Primary Institution: Nottingham City Hospital and Tenovus Institute for Cancer Research, University Hospital of Wales
Hypothesis
Can a combination of tumor markers provide an objective measure of therapeutic response in metastatic breast cancer?
Conclusion
The study found that a combination of five tumor markers can accurately reflect therapeutic response in over 90% of patients receiving endocrine therapy for metastatic breast cancer.
Supporting Evidence
- The overall response rate was 26% using UICC criteria after 6 months.
- 64% of ER positive patients showed response or disease stabilization.
- Significant correlations were found between therapeutic response and changes in serum concentrations of the five markers.
Takeaway
Doctors can use a mix of five blood tests to see how well treatment is working for breast cancer patients, helping them make better decisions about care.
Methodology
The study analyzed serum concentrations of five tumor markers in 179 patients receiving endocrine therapy for metastatic breast cancer over a 6-month period.
Potential Biases
Potential bias in patient selection and the retrospective nature of the study.
Limitations
The study was retrospective and may require further prospective validation to confirm the findings.
Participant Demographics
179 patients with advanced recurrent breast cancer, including 23% premenopausal women.
Statistical Information
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website